Systematic Elucidation of the Potential Mechanisms of Core Chinese Materia Medicas in Treating Liver Cancer Based on Network Pharmacology

Table 5

Results of KEGG pathway enrichment (top 20).

Name of pathways	Gene numbers	FDR
Hsa05200: pathways in cancer	50	2.62E − 18
Hsa05161: hepatitis B	32	2.03E − 17
Hsa04151: PI3K-Akt signaling pathway	30	1.86E − 05
Hsa05152: tuberculosis	25	2.35E − 08
Hsa05215: prostate cancer	24	2.09E − 14
Hsa04668: TNF signaling pathway	24	2.42E − 12
Hsa04010: MAPK signaling pathway	24	1.66E − 04
Hsa05166: HTLV-I infection	24	1.78E − 04
Hsa05164: influenza A	23	6.95E − 07
Hsa05205: proteoglycans in cancer	23	1.00E − 05
Hsa05206: micro-RNAs in cancer	23	0.005433
Hsa05145: toxoplasmosis	22	5.30E − 10
Hsa05160: hepatitis C	21	1.92E − 07
Hsa04510: focal adhesion	21	4.05E − 04
Hsa05212: pancreatic cancer	20	1.71E − 12
Hsa04066: HIF-1 signaling pathway	20	3.78E − 09
Hsa05142: Chagas disease (American trypanosomiasis)	20	1.69E − 08
Hsa04620: toll-like receptor signaling pathway	20	2.40E − 08
Hsa04024: cAMP signaling pathway	19	0.004254
Hsa04014: Ras signaling pathway	19	0.026935